Vascular Disease in 50s Begets Brain Amyloid in 70s
Prospective study links cardiovascular risk factors to brain amyloid.
6538 RESULTS
Sort By:
Prospective study links cardiovascular risk factors to brain amyloid.
In the field’s march toward automated testing, scientists for the first time used biomarker cutoffs determined in one cohort to predict amyloid accumulation in a second. It worked.
In tauopathy mice, ApoE4 hastened neuroinflammation and neurodegeneration. No amyloid involved. (Tip: Think A1 astrocytes.)
Next-Generation Tau PET Tracers Strut Their Stuff Are CSF Assays Finally Ready for Prime Time? ApoE and Tau: Unholy Alliance Spawns Neurodegeneration New Evidence Confirms TREM2 Binds Aβ, Drives Protective Response Location, Conformation, Decoration: Tau
The receptor responds to brain insults such as oligomeric Aβ and cellular debris by jolting microglia into clean-up mode, according to researchers at AD/PD 2017.
TIMP2 and possibly other human plasma proteins reinvigorate aged hippocampi in mice.
For their work on modifiable dementia risk factors and dementia in the oldest old, respectively, Kristine Yaffe and Claudia Kawas split this year’s coveted award in neurodegeneration research.
Need another reason to grab water instead of a soda? Beverages with added sugar—natural or artificial—are linked to smaller brain volume, worse memory, and tripled odds of stroke and dementia.
Showcasing forays into the biology of tau, researchers at AD/PD reported news on tau’s transcriptional regulation, its bungling of synaptic vesicles, its sway over the epigenome, and even flashed an atomic structure.
As the brain ages, what protects it from cognitive decline? A two-day conference focused on reserve and resilience.
Overexpressing miR-132 dampened AD pathology in young mice, and appeared to nourish the birth of new hippocampal neurons in older animals.
NIH Summit Examines What Makes a Healthy Aging Brain
Manufacturers of a therapy system called neuroAD, which combines transcranial magnetic stimulation with cognitive training, are applying for FDA marketing clearance.
Three anti-tau antibodies are in Phase 1 or 2, while an O-GlcNAcase inhibitor got the green light to start testing.
Using torpedo-like DNA snippets to delete mRNAs from cells, scientists lowered the amount of ataxin-2 protein. This allayed disease in mouse models of two neurodegenerative disorders.
No filters selected